A recent study published in the Journal of the European Academy of Dermatology and Venereology (JEADV), proposed that treatment of psoriasis vulgaris with calcipotriol (Cal) and betamethasone propionate (BD) foam therapy showed superior efficacy when compared to monotherapies or other formulations of Cal/BD.
The study included a comparative analysis between Cal/BD foam therapy and other psoriasis treatments including monotherapies with Cal/BD, Cal/BD ointments, Cal/BD gel, medicated plasters etc. The study was was divided into two phases following the established early phase I safety and efficacy studies: phase II and phase III.
Phase II involved a comparative analysis between Cal/BD foam treatment and Cal foam, BD foam and Cal/BD ointment. A total of 302 adult patients with psoriasis were enrolled into the study, evaluating the effect of Cal/BD foam treatment in patients with body psoriasis and scalp psoriasis. The treatment success was evaluated based on the Physician’s Global Assessment (PGA) criteria as ‘clear’ or ‘almost clear’.
The treatment success was measured after 4 weeks, showing a greater percentage of ‘clear’ or ‘almost clear’ results in patients treated with Cal/BD foam, when compared to Cal foam, BD foam or Cal/BD ointment. Phase III included a randomised comparative study between Cal/BD foam and Cal/BD gel. The treatment success showed significantly greater PGA ‘clear” or ‘almost clear’ results with Cal/BD foam.
Thus, the combined results of all three phases of the study indicated that a fixed-dose Cal/BD foam treatment is safe and effective for the treatment of psoriasis when compared to their individual/combined components in a gel or ointment form. Furthermore, Cal/BD foam has been established as an adjunctive therapy to stable biologic treatments.
Source: Stein Gold L, Paul C, Romiti R. Efficacy and safety of fixed‐dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. (2021); 35(S1):10-19.